
Electrocardiographic Safety of Daily Hydroxychloroquine 400 mg Plus Azithromycin 250 mg as an Ambulatory Treatment for COVID-19 Patients in Cameroon
Author(s) -
Liliane Mfeukeu-Kuaté,
William Ngatchou,
Mazou Ngou Temgoua,
Charles Kouanfack,
Daniel Lemoungoum,
Joël Noutakdie Tochie,
Armel Zemsi,
Lauriane Nomene Fomete,
Skinner Lekelem,
Sylvain Zemsi,
Joelle Sobngwi,
Thierry Ntandzi,
Christian Ngongang Ouankou,
Yves Wasnyo,
Antoinette Tsama Assiga,
Jan René Nkeck,
Ahmadou Musa Jingi,
Magellan Guewo,
Eric Walter Pefura Yone,
Charlotte Moussi Omgba,
Paul Owono Etoundi,
Jean Cyr Yombi,
Samuel Kingué,
Alain Menanga,
Jacqueline Zé Minkande,
Pierre Ongolo Zogo,
Jean Claude Mbanya,
Pierre Joseph Fouda,
Eugène Sobngwi
Publication year - 2021
Publication title -
world journal of cardiovascular diseases
Language(s) - English
Resource type - Journals
eISSN - 2164-5337
pISSN - 2164-5329
DOI - 10.4236/wjcd.2021.112012
Subject(s) - medicine , azithromycin , hydroxychloroquine , qt interval , ambulatory , qrs complex , covid-19 , clinical endpoint , prospective cohort study , confidence interval , cohort , anesthesia , clinical trial , disease , infectious disease (medical specialty) , microbiology and biotechnology , biology , antibiotics